2021-11-16-世界卫生组织-Cervical_cancer_Estonia_2021_country_profile_1页_64kb

Estonia Cervical Cancer Profile Summary

Morbidity and Mortality

• Crude incidence rate: 28.1 per 100,000 women in 2020
• Age-standardized incidence: 18.5 per 100,000 women in 2020
• Cumulative risk (ages 0-74): 1.9% in 2020
• Cervical cancer deaths: 8,100 female deaths in 2019
• Mortality-to-incidence ratio: 0.32 in 2020
• Population-based cancer registry exists (2021)

Primary Prevention (HPV Vaccination)

• Vaccination programme: Introduced in 2018, national scale for girls aged 12-14; HPV included in national programme, programme coverage 59% by 2018
• Coverage by age 15: 55% completed final dose by age 15
• Related risk factors: HPV vaccination uptake details provided, including targets and gaps
• Other risks: Tobacco use prevalence among women aged 15+: 19%; HIV incidence per 1000 among women aged 15+: 0.13

Secondary Prevention (Screening)

• National cervical cancer screening programme exists (2021); primary screening test is cytology
• Target age range: 30-55 years
• Ever screened: 85% of women in target age group
• Screening in last 5 years: 57% of women aged 30-55
• Programme/guidelines: Exist for early detection at primary health care, with a clearly defined referral system to secondary and tertiary care

Treatment and Supportive Care

• National guidelines on cervical cancer management exist (2021)
• Resources: Radiotherapy units: 4 per 10,000 cancer patients in 2020; brachytherapy units: 18 in 2020
• Staff: Medical staff per 10,000 cancer patients: 10; radiation oncologists: 2019; medical physicists: 2019; surgeons: 2014; radiologists: 2019
• Cancer treatment services generally available, including radiotherapy, chemotherapy, palliative care, and cancer centres at tertiary level
• WHO elimination strategy targets referenced for 2030